Maternal demographic and clinical characteristics of patients diagnosed with an isolated short femur compared with controls.

<p>¹Student’s t-test</p><p>²Chi-square test</p><p>SD: standard deviation, BMI: body mass index, FL: femur length</p><p>Maternal demographic and clinical characteristics of patients diagnosed with an isolated short femur compared with controls.</p

Perinatal outcome in fetuses with isolated short femur length compared with controls.

<p>¹Student’s t-test</p><p>²Chi-square test</p><p>SD: standard deviation, SGA: small for gestational age, LBW: low birth weight, NICU: neonatal intensive care unit</p><p>Perinatal outcome in fetuses with isolated short femur length compared with controls.</p

Flowchart.

<p>The process of inclusion and exclusion of patients in order to find the sample of patients included in the present study (= 165).</p

Median duration of chemotherapy broken down by clinical and pathological parameters.

<p>Median duration of chemotherapy broken down by clinical and pathological parameters.</p

Patients’ characteristics (n = 165).

<p>Patients’ characteristics (n = 165).</p

Survival curves.

<p>Kaplan Meier curves for patients stratified into risk groups according to the delay of total chemo-duration are given for progression-free (PFS), cancer-specific (CSS), and overall survival (OS) in figures A, B, and C, respectively. 5-year rates of PFS, CSS and OS for each risk group are given in the table below.</p

Hazard ratios of uni- and multivariable analyses for the association between delay of total chemo-duration and progression-free (PFS), cancer-specific (CSS), and overall survival (OS).

<p>Hazard ratios of uni- and multivariable analyses for the association between delay of total chemo-duration and progression-free (PFS), cancer-specific (CSS), and overall survival (OS).</p

Characteristics of 114 patients with primary metastatic breast cancer.

<p>HR = hormonal receptor (estrogen and/or progesterone receptor), GGT = gamma-glutamyltransferase, HER2 = human epidermal growth factor 2-receptor</p><p>Characteristics of 114 patients with primary metastatic breast cancer.</p

Univariate and multivariable overall-survival analyses.

<p>^aKaplan—Meier analysis (log-rank test)</p><p>^<b>b</b>Multivariable Cox-regression analysis</p><p>*mean (SD) age: 61.0 (13.4) years; GGT = gamma-glutamyltransferase, HER2 = human epidermal growth factor 2-receptor, OS = overall survival, HR = hazard ratio, 95% CI = 95% Confidence Interval</p><p>Univariate and multivariable overall-survival analyses.</p

Pre-therapeutic GGT serum levels of patients with primary metastatic breast cancer broken down by clinical-pathological parameters.

<p>* One-way ANOVA</p><p>⁺ Student’s T-test</p><p>^⇞ Values are given as mean (standard deviation), GGT = gamma-glutamyltransferase, HER2 = human epidermal growth factor 2-receptor, SD = standard deviation</p><p>Pre-therapeutic GGT serum levels of patients with primary metastatic breast cancer broken down by clinical-pathological parameters.</p